Reinhart Partners Loads Up on $20 Million Worth of AdaptHealth Shares

Reinhart Partners added 1,981,198 shares of AdaptHealth in Q1, an estimated $20.2 million purchase that increased its stake by roughly 24% and lifted the position to 10.1 million shares valued at $120.0 million. The stock now represents about 3.5% of AUM, though the fund’s purchase was only a 0.6% AUM change, limiting broader market impact. The article is modestly constructive on AdaptHealth given improved financing with a new $1.1 billion credit facility and 2026 EBITDA guidance of $680 million to $730 million, despite recent EPS pressure.

Analysis

Reinhart’s add is more useful as a signal on underwriting confidence than as a valuation argument. When an existing holder ups a mid-cap healthcare services name by roughly a quarter, it usually implies the thesis has shifted from “recovery optionality” to “operational inflection,” especially when the company just refinanced and pushed out balance-sheet risk. The market is still discounting execution risk more heavily than funding risk, so the stock can continue to re-rate if management converts guidance into visible margin and cash-flow improvements over the next 2-3 quarters.

The second-order winner is likely the company’s creditor stack and, indirectly, other outsourced home-care providers with similar reimbursement exposure. Improved financing terms reduce equity overhang and should lower the probability of dilutive capital actions; that matters because in this segment, valuation often hinges on whether growth can be funded without balance-sheet stress. If the large capitated contract ramps cleanly, the market may start valuing the business on recurring revenue durability rather than legacy reimbursement noise, which can compress the discount applied to the entire HME group.

The main risk is that the operating lever is not just revenue growth but execution on working capital, labor, and claims processing. Home medical equipment businesses can look deceptively stable until payor friction or implementation issues create a cash conversion gap; that would show up before earnings do. The next 1-2 quarters are the key catalyst window: if EBITDA guides to the high end and leverage trends down, the stock can keep working; if the contract ramps slowly or impairment-like items recur, the crowd will quickly reframe this as a low-quality earnings story.

Contrarian view: the consensus may be overestimating how much of the “easy” balance-sheet de-risking is already in the price. A 54% trailing move plus better credit access means a lot of the obvious bull case has been recognized, so upside now depends on true operating beats, not just multiple expansion. That makes this more attractive as a catalyst-driven trade than a long-duration core holding unless evidence of sustained free-cash-flow conversion emerges.

Key Decisions for Investors

• Long AHCO on a 3-6 month horizon, but size modestly; use the post-financing setup as a catalyst trade, with a target tied to confirmation of EBITDA guidance rather than hero multiples.
• Buy AHCO call spreads into the next earnings print if implied volatility is still reasonable; structure for upside on a clean ramp while capping premium at risk if contract execution slips.
• Pair long AHCO / short a basket of weaker healthcare services names with higher leverage and weaker refinancing optionality; the trade expresses balance-sheet de-risking over generic sector beta.
• If AHCO fails to show improving cash conversion in the next 1-2 quarters, fade the move via a tactical short or put spread; the risk/reward flips quickly if the market stops believing in the capitated contract thesis.
• Avoid chasing the stock after sharp strength; wait for pullbacks toward support or for evidence that the new credit facility is translating into lower net leverage and better FCF.